IL13RA2 and central nervous system cancer: In this study, we evaluated that the expression of IL-13Rα2 and FUS in 48 clinical glioma specimens, preliminarily analyzed their relationship with clinicopathological parameters and performed a survival analysis to further infer their value as biomarkers that have prognostic, predictive, and clinical applications in glioma subtypes.